Stevens-Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulins;Síndrome de Stevens-Johnson/necrolisis epidérmica tóxica tratado con inmunoglobulinas intravenosas

Actas Dermo-Sifiliograficas

Volumn 96, Issue 9, 2005, Pages 589-592

  Yuste, Manuela ^a,b   Sánchez Estella, Juan ^a   Santos, Juan C ^a   Alonso, Ma Teresa ^a   Bordel, Ma Teresa ^a   Gutiérrez, José L ^a   Zamora, Tomás ^a  

^a HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^b Hospital Virgen de la Concha ^*  (Spain)

Author keywords

Intravenous immunoglobulins; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CORTICOSTEROID; GINKGO BILOBA EXTRACT; IMMUNOGLOBULIN;

AGED; ARTICLE; CASE REPORT; CELL DEATH; DEPRESSION; ENTROPION; EPITHELIZATION; FACE ERYTHEMA; FEVER; HEADACHE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IMMUNOTHERAPY; KERATINOCYTE; MALE; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

EID: 30344483199     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0001-7310(05)73141-0     Document Type: Article

References (22)

1. García I, Roujeau JC, Cruces Prado MJ. Necrolisis epidérmica tóxica y síndrome de Stevens-Johnson: clasificación y actualidad terapéutica. Actas Dermosifiliogr. 2000;91:541-51.
2. García D, García Patos V, Castells A. Síndrome de Stevens-Johnson/necrolisis epidérmica tóxica. Piel. 2001;16: 444-57.
3. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol. 2001;1:349-60.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Arch Dermatol. 2002;138:1019-24.
5. Gatti CF, Rodríguez MC, Cha DM, Barquin MA. Necrolisis epidérmica tóxica inducida por lamotrigina. Tratamiento con inmunoglobulina intravenosa. Med Cutan Ibero Lat Am. 2003;31:182-6.
6. Chiu AE, Lane AT, Kimball AB. Diffuse morbiliform eruption after consumption of ginkgo biloba supplement. J Am Acad Dermatol. 2002;46:145-6.
7. Sanwo M, Nwadiuko R, Beall G. Use of intravenous immunoglobulin in the treatment of severe cutaneous reactions in patients with AIDS. J Allergy Clin Immunol. 1996; 98:1112-5.
8. Rütter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol. 2001;44:1010-24.
9. Molgó M, Casasas A, Salas I. Uso de Inmunoglobulina humana intravenosa en la necrolisis epidérmica tóxica. Piel. 2001;16:315-8.
10. Nassif A, Moslehi H, Le Gouvello S, et al. Evaluation of the potencial role of cytokines in Toxic Epidermal Necrolysis. J Invest Dermatol. 2004;123:850-5.
11. Fernández-Figueras MT, Puig L. Claves para el diagnóstico dermatopatológico. Toxicodermias. Piel. 2002;17:74-80.
12. Roujeau JC. Treatment of severe drug eruptions. J Dermatol. 1999;26:718-22.
13. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol. 2003;139:39-43.
14. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol. 1998;134:80-6.
15. García J, De Miguel D, Burgaleta C. Indicaciones del empleo de inmunoglobulinas intravenosas. Rev Clin Esp. 2002;202:157-60.
16. Viard I, Nehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD 95 with human intravenous immunoglobulin. Science. 1998;282:490-3.
17. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Arch Dermatol. 2003;139:26-32.
18. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective non comparative study showing no Benefit on mortality or progresión. Arch Dermatol. 2003;139:33-6.
19. Brown KM, Silver GM, Halerz M, Walaszek P, Sandroni A, Gamelli RL. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81-8.
20. Shortt R, Gómez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246-55.
21. Wolf J, Tappeiner G. Treatment of toxic epidermal necrolysis. Arch Dermatol. 2003;139:85-6.
22. Hebert A, Bogle M. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol. 2004;50:286-8.